Health Economics of Digital Therapeutics and Virtual Care (Pharmaceuticals)

(Pharmaceuticals) Saudi Arabia is emerging as a global leader in digital healthcare adoption, underscored by a USD 1.5 billion national investment into virtual care infrastructure and the scaling of the Seha Virtual Hospital, which processes hundreds of thousands of remote consultations annually. Clinical AI is being integrated into care pathways across all 21 regional clusters. This forward-looking course examines the intersection where digital therapeutics (DTx) and AI diagnostic software meet traditional pharmaceutical interventions, equipping digital health and market-access professionals to value and commercialize a new class of assets. Participants explore the non-traditional health economics of digital and remote interventions, learning why conventional drug valuation frameworks must be adapted for software-based therapies with continuous engagement, iterative updates, and data-driven effects. The curriculum teaches participants to value continuous remote monitoring tools and to demonstrate how the digitization of unified health records can be leveraged to track, prove, and monetize long-term clinical outcomes within performance-based contracts. Through applied case work grounded in the Saudi virtual-care landscape, participants build economic models for DTx, design evidence strategies suited to digital products, and structure reimbursement arguments for value-based payers. The outcome is a practical capability to position digital interventions as economically defensible, outcome-generating health solutions.